South Dakota Investment Council trimmed its stake in shares of Sanofi SA (NYSE:SNY) by 13.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,080 shares of the company’s stock after selling 1,360 shares during the quarter. South Dakota Investment Council’s holdings in Sanofi were worth $402,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently bought and sold shares of SNY. Quadrant Capital Group LLC lifted its stake in shares of Sanofi by 259.5% in the 4th quarter. Quadrant Capital Group LLC now owns 12,187 shares of the company’s stock valued at $511,000 after purchasing an additional 8,797 shares during the period. MML Investors Services LLC lifted its stake in shares of Sanofi by 17.6% in the 4th quarter. MML Investors Services LLC now owns 29,297 shares of the company’s stock valued at $1,272,000 after purchasing an additional 4,391 shares during the period. Wetherby Asset Management Inc. lifted its stake in shares of Sanofi by 11.1% in the 4th quarter. Wetherby Asset Management Inc. now owns 35,988 shares of the company’s stock valued at $1,563,000 after purchasing an additional 3,596 shares during the period. Employees Retirement System of Texas lifted its stake in shares of Sanofi by 288.2% in the 4th quarter. Employees Retirement System of Texas now owns 164,769 shares of the company’s stock valued at $7,153,000 after purchasing an additional 122,327 shares during the period. Finally, Nkcfo LLC purchased a new position in shares of Sanofi in the 1st quarter valued at approximately $35,000. Institutional investors and hedge funds own 7.04% of the company’s stock.

In other Sanofi news, major shareholder Sanofi sold 131,115 shares of the business’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $412.17, for a total transaction of $54,041,669.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 1.00% of the company’s stock.

SNY has been the subject of a number of recent research reports. TheStreet cut Sanofi from a “b” rating to a “c+” rating in a research note on Thursday, February 7th. HC Wainwright reiterated a “buy” rating on shares of Sanofi in a research note on Thursday, February 28th. Finally, Zacks Investment Research cut Sanofi from a “buy” rating to a “hold” rating in a research note on Tuesday, February 5th. Eight investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $51.00.

NYSE:SNY opened at $41.05 on Thursday. Sanofi SA has a 52-week low of $37.67 and a 52-week high of $45.62. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.22 and a quick ratio of 0.85. The stock has a market cap of $102.96 billion, a price-to-earnings ratio of 13.12, a P/E/G ratio of 2.41 and a beta of 0.67.

Sanofi (NYSE:SNY) last released its quarterly earnings results on Friday, April 26th. The company reported $0.81 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.07. Sanofi had a return on equity of 18.18% and a net margin of 12.20%. The business had revenue of $8.39 billion during the quarter, compared to analyst estimates of $8.34 billion. During the same quarter in the previous year, the company posted $1.28 earnings per share. Sanofi’s revenue for the quarter was up 6.2% on a year-over-year basis. Equities research analysts predict that Sanofi SA will post 3.1 EPS for the current year.

The business also recently declared an annual dividend, which will be paid on Friday, May 31st. Shareholders of record on Wednesday, May 8th will be issued a dividend of $1.7395 per share. This represents a yield of 4.2%. The ex-dividend date of this dividend is Tuesday, May 7th. Sanofi’s dividend payout ratio is presently 37.38%.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://www.dailypolitical.com/2019/05/16/south-dakota-investment-council-sells-1360-shares-of-sanofi-sa-sny.html.

Sanofi Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Featured Article: Differences Between Momentum Investing and Long Term Investing

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.